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Molecularly-targeted therapeutics and personalized medicine have dramatically increased 
the median survival rate of patients suffering from cancer. However, cellular heterogeneity and the 
personalized nature of cancer have resulted in the limited success of single drug treatments which 
has led to the use of multiple therapeutic combinations. This has required the development of new 
analytical methods capable of multiplexed high-throughput screening (HTS) technologies 
necessary to identify is single or multi-agent therapies are effective in ex vivo samples like liquid 
biopsies. Droplet microfluidic devices have garnered significant interest to facilitate high-
throughput, single cell analysis of heterogeneous populations. However, these devices are still 
limited in their ability to assess multiple input conditions such as combinations of multiple drugs 
or different doses of the same drug. Moreover, HTS approaches need to be coupled with automated 
image analysis metrics capable of rapidly processing raw data and quantifying it in an efficient 
manner.  
The goal of this work is to address these two areas of need by developing a new method to 
track different inputs in a droplet microfluidic trapping array coupled with automated image 
analysis of single cell behavior. The first part of this study highlights the use of rare-earth (RE)-
doped luminescent nanoparticles (NP) as novel method to track input conditions in droplets in a 
microfluidic device. The second part of the work deals with the development of an algorithm called 
FluoroCellTrack to efficiently analyze single cell data from high-throughput experiments in the 
droplet microfluidic trapping array. The β-hexagonal NaYF4 nanoparticles used for droplet 
tracking were doped with a rare-earth emitter with unique spectral properties that do not overlap 
with established fluorophores like GFP and Rhodamine. In this study, we employed europium as 
the dopants which has a luminescence emission spectrum in the red region upon UV excitation. 
We demonstrated that the RE-doped nanoparticles are biologically inert and spectrally independent 
with common fluorophores and fluorescent stains. This work provided a foundation for future 
applications using the combination of NPs and microfluidics for multiplexed droplet tracking to 
quantify tumor heterogeneity and assess the effectiveness of combinatorial therapies. To perform 
HTS of single cells, a Python algorithm (FluoroCellTrack) was developed to: (i) automatically 
distinguish droplets from cells, (ii) count cells in each droplet, (iii) quantify cell viability, and (iv) 
identify input conditions using the RE-doped nanoparticles. The performance of FluoroCellTrack 
was compared to manual image analysis with a difference in intracellular quantification of ~2% 
coupled with a decrease in analysis time of <10 minutes over 20 hours of manual analysis. The 
applications for this algorithm are numerous including fluorescence quantification, droplet 
barcoding and biomarker detection.
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1. BACKGROUND AND SIGNIFICANCE 
1.1 Cancer and the Need for Personalized Medicine 
Cancer is one of the leading causes of deaths in the United States with more than 1.6 million 
new cases of cancer having been diagnosed this year resulting in over 600,000 deaths per year 
during the past decade. This is due to the fact that conventional cancer treatment options including 
chemotherapy, hormonal, and antiangiogenic therapies often result in high toxicity and have low 
treatment efficacy.[2] For decades, these traditional therapies have not accounted for genetic 
variability of individuals and treatment protocols were made based on indirect results of cells at 
the population level.  In addition, acquired drug resistance due to intratumor heterogeneity further 
decreased the efficacy of single-target drug treatment.[2, 3] This led to the development of 
combinatorial therapies, wherein multiple oncogenes are targeted simultaneously, resulting in a 
more personalized approach to medicine. Personalized medicine is achieved through targeted 
therapeutics and pharmacogenomics. Pharmacogenomics deals with the understanding of how a 
person’s genes affect the way the body processes and responds to drugs while molecularly-targeted 
therapeutics involve the development of drugs towards critical biochemical pathways (like the 
ubiquitin-proteasome system, the autophagy lysosome system, and aggresome formation) and 
dysregulated enzymes (like kinases and phosphatases).[4] Several drugs like Trastuzumab and 
Lapatinib have been used to inhibit protein kinase in breast cancer.[4, 5] Another example is the 
development of clinically successful drugs like Bortezomib and Carfilzomib which inhibit 
proteasome, an enzymatic complex associated with the ubiquitin-proteasome system (UPS) of 
multiple myeloma.[6] There is clinical evidence of a drastic reduction in tumor size in breast cancer 
patients when lysosomal-based therapeutics have been coupled with drugs designed to inhibit 
deubiquitinating enzyme (DUBs), another enzyme in the UPS, highlighting the merits of 
combinatorial therapies.[7] The advantage of combinatorial therapeutics is further validated by 
network models which suggest that partial inhibition of a number of different targets is more 
effective than complete inhibition of a single target.[5] As a result, the major goal of personalized 
medicine is to give cancer patients the treatments that are most likely to work on their cancer with 
fewer harmful side effects. 
1.2 High-Throughput Microfluidic Devices and Barcoding Technology: A Key Diagnostic 
Tool in Cancer 
Tumor heterogeneity is defined by the fact that distinct cancer cells within a genetically 
identical population can exhibit different morphological and phenotypic profiles like cell 
proliferation, metabolism, and death.[4] To fully understand this cell-to-cell variability, a complete 
analysis of individual cells across an entire population is critical. Single cell technologies enable 
the quantification of the individual cellular response to drugs and the identification of drug-
resistant subpopulations in a tumor environment which are otherwise lost in population averaged 
measurements.[8-10] Conventional methods including single cell PCR quantification and 
fluorescent in-situ hybridization (FISH), only provide indirect evidence of protein behavior and 
are limited in their need for large sample sizes and their inability to account for tumor 
heterogeneity.[10] Existing high-throughput single-cell analysis techniques include mass 
cytometry, fluorescent and magnetic activated cell sorting (FACS, MACS) have been widely 
adopted in modern labs.[8, 10] However, dynamic cell responses cannot be monitored with these 
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techniques, since data are collected at a single time point. Despite the development of these high-
throughput single cell analysis tools, a recurring challenge in single cell analysis is to achieve a 
precise, sensitive, high-throughput and economic way to detect and analyze a diverse population 
of cells.[11] Microfluidics is an emerging solution in addressing these issues by providing low 
reagent costs, ease of automation, scalability, room for multi-step integration, improved cell 
handling, and dynamic observation.[11, 12] Figure 1.1 shows one of the earliest droplet microfluidic 
devices developed by Stephen R. Quake et. al in 2001.[1] Droplet microfluidics is among the most 
promising candidates for capturing and processing thousands of individual cells. Droplet based 
microfluidic devices uses a 2-phase system, in which each assay is compartmentalized in aqueous 
droplets surrounded by an immiscible oil.[13] The advantage of this droplet-based technique is that 
it enhances the sensitivity of single cell assays by generating picoliter-sized droplets, thus 
localizing single cell studies. These droplet microfluidic devices are also used with fluorescent 
barcoding techniques which has led to the creation of a holistic diagnostic system capable of 
multiplexed, high-throughput analysis of single cells.[14, 15] One such recent achievement was to 
use droplet microfluidic devices in barcoding parallel single DNA molecules.[15] Several barcoding 
techniques have been implemented in droplet microfluidic devices including graphic, 
spectroscopic, electronic, and physical encoding of the droplets.[16]  
 
Figure 1.1- Vesicle generating microfluidic device.[1]  A) Microfabricated channel dimensions at 
the point of crossflow B) photomicrograph of the discontinuous water phase introduced into the 
continuous oil phase. Dashed rectangle indicates area in photomicrograph. 
 
Recent technologies in micro-scale cancer diagnostics like inDrops is a combination of 
spectroscopic barcoding and microfluidic technologies.[17] However, such techniques make use of 
expensive antibodies and complex PCR reactions which are time consuming and can require 
several steps to generate the barcoding signal. Advances in nanomaterials have produced a new 
class of fluorescent labels by conjugating semiconductor quantum dots (QDs) with biorecognition 
molecules.[18, 19] These QDs are highly stable to photobleaching, have narrow, symmetric emission 
spectra, and size-tunable wavelength.[19] Even though quantum dots offer several advantages over 
organic dyes[16], their surface coatings and surface defects can affect the viability of cells.[20] Most 
of the existing QD approaches have disadvantages such as lack of flexibility, reaction speed, and 
repeatability. Thus, active research is underway to develop a more adaptable, inexpensive, and 
viable combination of high-throughput microfluidic and droplet barcoding techniques.  
 
1.3 High-throughput Automated Image Analysis 
Microfluidics and droplet barcoding are powerful tools to study and manipulate biological 
systems.[11] Droplet microfluidic technologies consisting of micro wells or trapping arrays are 
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capable of segregating and studying single and multiple cells in thousands of parallel 
experiments.[13, 15] The increase in such high-throughput cellular studies have generated a need for 
rapid, automated screening and analysis tools that are capable of efficient acquisition, processing 
and analysis of data. Advancements in digital imaging has made it possible to capture real-time, 
dynamic events on micro- and nano-scale levels.[21, 22] But, there is a growing need in the biological 
research community for robust and accurate analysis tools to quantitatively measure the intricate 
details in these high-throughput experiments.[23, 24] Manual cell counting has been widely used to 
quantify fluorescent microscopy data; however, this is a very tedious process and the results can 
be highly subjective. Moreover, advanced processing techniques such as pattern recognition and 
cell image segmentation must be employed for these biological applications to be quantified. 
Several semi-automatic (individual algorithms that can be modified by a user) and automatic 
(complete analysis package) platforms have been proposed for image-processing applications in 
biomedical research.[22-24] Existing software such as ImageJ[25] and CellProfiler[26] can detect cells, 
but are not suitable for automated microwell or array recognition, thus making them incompatible 
with droplet trapping or cell encapsulation experiments.[27, 28] CellProfiler segregates cells by “grid 
analysis” and ImageJ by macros to defined regions of interest (ROI), but these approaches may 
not be suitable to process many images in a high-throughput manner. Proprietary software such as 
Genepix and Quantarray allow the user to define individual microwells on an image but they 
cannot recognize patterns automatically within the images.[27] Moreover, all of these software 
packages are limited to quantify variations in fluorescent intensities and cannot be used to count 
cells within droplets or characterize populations of cells based user-defined differences. A 
summary of other commonly used software, their features and drawbacks are listed in Table 1.1.[28] 













Can only be used in 
fluorescence microscopy. 
Cannot count cells. 
wndchrm No None C 
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to count nuclei, but does not 
give the number of cells in 
individual array spots. 
ScanCount, 
CHiTA 
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1.4 Project Objective 
The goal of this project was to combine spectrally independent, biologically benign 
inorganic nanoparticles with a droplet microfluidic trapping array to develop a new analytical 
droplet trapping technique capable of high-throughput, single cell analysis of combinatorial drug 
treatments across a population of cells. In this work, we used europium doped nanoparticles (NPs) 
as droplet barcodes. These NPs were synthesized and co-encapsulated with cancer cells within 
aqueous microdroplets and screened across the trapping array. This successful proof of concept 
showed that these NPs can be potentially employed as spectrally independent luminescent markers 
for multiplexed droplet tracking facilitating simultaneous the screening of patient-derived ex vivo 
samples in response multiple combinatorial therapeutics.  
 
Figure 1.2 – Rare earth (RE), luminescent particles for high-throughput microfluidic droplet 
barcoding. Co-encapsulation of RE-doped nanoparticles with cancer cells and various drug 
combinations on a microfluidic droplet trapping array to perform high-throughput screening of 
single cells followed by automated analysis of fluorescence microscopy images to obtain 
quantified results. 
Further, a Python algorithm was developed to analyze microscopy images of cells 
encapsulated in droplets trapped in the microfluidic array by (i) automatically distinguishing 
droplets from cells, (ii) count cell(s) in each droplet and account for viability (iii) quantify 
intracellular fluorescence in each cell and so on. High magnification bright field and fluorescence 
microscopy images of these experiments were captured and analyzed with the developed 
algorithm. Overall, a novel high-throughput droplet microfluidic barcoding technique and an 
algorithm for automated image analysis were developed as shown in Figure 1.2. 
1.5 Overview of Thesis 
This first chapter introduces the importance of microfluidics and barcoding technologies 
as key diagnostic tools of personalized medicine in cancer. It also discusses the problems that exist 
with the current approaches to high-throughput single cell analysis, and automated image analysis.  
Chapter 2 describes the high-throughput droplet tracking technique with luminescent 
nanoparticles in a microfluidic droplet trapping array. This chapter describes the features of the 
luminescent nanoparticles, microfluidic device, experiment methodology, qualitative and 
quantitative results.   
Chapter 3 describes the Python algorithm called FluoroCellTrack that was developed to 
process, analyze and extract useful quantitative data from the fluorescent microscopy images.  
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Chapter 4 finally gives the conclusions from this project and recommendations for further 














































2. HIGH-THROUGHPUT DROPLET TRACKING WITH LUMINESCENT 




Genomic diversity and clonal evolution in cancer has led to substantial intra-tumor 
heterogeneity where multiple clonal subpopulations of cancer cells express different properties 
including growth rate, immunological characteristics, production and expression of markers etc.[29] 
These irregularities manifest diversely despite patients being classified identically due to the 
heterogeneity associated with the majority of cancers.[29, 30] Such complex nature of cancer has 
resulted in a limited success of single drug treatments leading to the development of combinatorial 
therapies, wherein multiple oncogenes are targeted simultaneously, resulting in a push for a more 
personalized approach to medicine.[31] One area of personalized medicine is the development of 
molecularly-targeted therapeutics towards critical biochemical pathways (like ubiquitin 
proteasome system, autophagy lysosome system) and dysregulated enzymes (like kinase).[4] 
Several drugs like Trastuzumab and Lapatinib have been used to inhibit protein kinase in breast 
cancer.[5] Another example is the development of clinically successful drugs like Bortezomib[32] 
and Carfilzomib[33] which inhibit proteasome, an enzyme associated with the ubiquitin proteasome 
system (UPS) of multiple myeloma. There is also clinical evidence of drastic reduction in tumor 
size with respect to breast cancer, when lysosomal based therapeutics have been coupled with 
drugs designed to inhibit deubiquitinating enzyme (DUBs), another enzyme in the UPS, 
highlighting the merits of combinatorial therapies.[6, 34] While the implementation of molecularly-
targeted therapeutics has improved the prognosis in cancer, the ability to screen patient samples 
against molecularly-therapeutics has lagged behind. Techniques to measure drug response in 
single, intact cells from a patient biopsy can improve diagnostics by providing direct information 
about the effectiveness of the drug target and drug concentration in treating an individual’s 
tumor.[35] Conventional methods including single cell PCR quantification and fluorescent in-situ 
hybridization (FISH), only provide indirect evidence of protein behavior and are limited in their 
need for large sample sizes and their inability to account for tumor heterogeneity.[36] To overcome 
this, researchers have developed high-throughput screening (HTS) technologies that are capable 
of analyzing a large population of cells in a relatively short period to identify subpopulations of 
cells in a heterogeneous sample. These HTS platforms are capable of assessing intact single cells 
within patient samples without any complex genetic manipulation of the cells prior to analysis. 
Example technologies include fluorescent and associated based cell sorting (FACS, MACS),[8] 
capillary electrophoresis[37] and microfluidics[13]. Fluorescent based sorting has traditionally been 
used for HTS, but analysis is often limited to cell surface markers and the technology cannot easily 
be incorporated into labs and clinics due to size and expense.  
Microfluidics offers a significant advantage over competing technologies due to reduced 
reagent costs, ease-of-use, significant reproducibility, and compatibility with fluorescent 
microscopy.[38, 39] Droplet microfluidic devices exhibit all of these advantages and are capable of 
HTS of intact single cells[12] and droplet barcoding for parallel single molecule DNA 
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sequencing[40]. While these microfluidic devices have helped revolutionize cancer screening 
techniques, they are still limited in their ability to simultaneously quantify a cellular output (e.g., 
death or intracellular enzyme activity) compared to a specific condition (e.g., concentration or 
number of drugs). This is due to the spectral overlap between established fluorescent biomarkers 
and droplet barcoding methods resulting in a limited number of simultaneous combinatorial 
treatments that can be investigated on a single device. In this work, this limitation is dealt by 
combining spectrally independent, biologically benign inorganic nanoparticles with a droplet 
trapping array to develop a new analytical technique capable of high-throughput, single cell 
analysis of combinatorial drug treatments across a population of cells.  
Over the past decade, inorganic luminescent nanoparticles such as quantum dots (QDs) 
have been widely used as fluorescent labels among biologists. QDs are endowed with 
distinguished characteristics such as small size (10 nm), photostability, narrow emission 
bandwidth, single-source excitation, and compatibility for multiplexed detection.[18] However, 
since their development in 1998,[41] there have been concerns with their application as probes in 
cell imaging, immunoassays, and single molecule detection due toxicity effects and difficult 
synthesize procedures.[20] The demand for effective fluorescent labels is still on-going. Another 
approach for novel biosensors incorporated rare-earth (RE) doped phosphors. The lanthanide 
series contains fifteen elements, lanthanum to lutetium (Z = 57 through 71), which along with 
yttrium and scandium, are collectively known as rare earth (RE) elements. A key aspect of Ln(III) 
ions as dopants is that, since the 4f sub-shell is well shielded by the 5s and 5p subshells, the energy 
of these 4f sub-shells are the least influenced by the surrounding environment which result in well-
defined and sharp absorption spectra.[42] This is in fact an attractive property of RE elements over 
transition elements, wherein the d-d transitions in the valence d shell of transition metals result in 
a spectrum of broadband nature.[43] Additionally, the f energy levels of the RE elements are 
conveniently spaced in specific energies, allowing an extended emission spectrum via two 
luminescence phenomena: upconversion (high energy to low energy conversion) and 
downconversion (low energy to high energy conversion). These different radiative phenomena are 
analogous to the anti-Stoke and Stokes shift observed in organic dyes, but with a more prominent 
shift of 100’s of nm over 10’s of nm.[44] The upconversion (UC) process is common in fluorescent 
bioimaging especially in in vivo studies due to the advantages of IR such as deep tissue penetration, 
weak background auto fluorescence, and low photobleaching. Upconversion has several other 
applications including photostimulation,[45, 46] to induce cell growth and in optogenetics[46] to 
stimulate neurons with near-infrared light. Unfortunately, these applications all require specific 
wavelengths that cannot be provided from a single phosphor, necessitating the synthesis of 
multiple, carefully designed particles. However, downconversion (DC) luminescence with UV 
excitation, offers unique benefits by providing a narrower emission range with ~50 nm windows 
for each element. While underutilized in biological applications, this ability to select specific 
colors offers an extensive palette for cell identification when performing ex vivo diagnostics.  
The work described in this chapter focuses on the use of RE -doped nanoparticles as droplet 
trackers using a downconversion fluorescent microscopy platform. Here, two different dopants 
(Eu3+, Tb3+) were incorporated into hydrothermally synthesized hexagonal β-NaYF4 nanocrystals. 
As a proof of concept, Eu3+-doped nanoparticles were tested here. These NPs, upon UV excitation 
have distinct excitation and emission spectra (europium in red) that do not overlap with commonly 
used fluorophores and fluorescent stains. The luminescent nanoparticles were characterized for 
structure, morphology, spectral properties, and biocompatibility using SEM, XRD, EDX and 
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photoluminescence studies.  Next, the RE-doped nanoparticles were encapsulated in picoliter sized 
droplets and trapped in a microfluidic droplet trapping array to confirm their potential as spectrally 
independent droplet tracker. A series of single cell and NP co-encapsulation experiments were 
performed to confirm the spectral independence of Eu3+-doped nanoparticles with green 
fluorescent protein (GFP), red fluorescent protein (RFP), and Ethidium Homodimer (EthD-1). The 
fluorescent microscopy data from these experiments were processed and analyzed to quantify the 
fluorescent signals from NP, fluorophores, and fluorescent stains; highlighting the spectral 
independence feature of these luminescent nanoparticles. The spectral independence of RE-doped 
NPs was further ascertained using ANOVA F-statistics.  
 
2.2 Materials and Methods 
2.2.1 Chemicals 
Yttrium(III) nitrate hexahydrate- 99.9% (Rare Earth Oxide - REO), Europium(III) nitrate 
hydrate - 99.99% (REO), Terbium(III) nitrate hydrate- 99.9% (REO) were purchased from Alfa 
Aesar. Sodium Citrate Dihydrate, ACS; Sodium Fluoride Solid, USP Grade; Hydrochloric Acid 
36.5-38.0% ACS were purchased from VWR International. 
 
2.2.2 Synthesis and Characterization of RE-doped Luminescent Nanoparticles 
Synthesis: A modified recipe from Li et. al[47] was used to synthesize high quality stable 
nanoparticles using a high temperature and high pressure hydrothermal process. In this process, 
Y(NO3).6H2O and RE (Eu
3+, Tb3+) nitrate were dissolved in 15 mL of water such that the 
percentage of RE doping is 2.5 to 10 mol%. To this, 2 mmol of sodium citrate (Na3 citrate = 1:4 
molar ratio) and 5 mL of 5M NaF aqueous solution were added. Sodium citrate (RE precursor) 
was added as a chelating agent to control the shape and morphology of the nanoparticles. After 10 
minutes of vigorous stirring, the pH of the solution was adjusted by adding 1 mL of reagent grade 
37% HCl and the hydrothermal reactor was sealed and heated at 180ºC for 3 hours. The reaction 
products were washed with DI water and ethanol several times to remove the organic impurities 
and neutralize the solution. To facilitate an α to β transition, annealing treatment at 400-600 ºC 
was done to achieve the desired morphology. NP with different dopant concentrations were 
synthesized by varying the dopant (X3+: Eu3+/Tb3+ concentration during this hydrothermal 
synthesis.  
Characterization: The synthesized nanoparticles were characterized for structure and 
morphology using Powder X-ray Diffraction (XRD) and Scanning Electron Microscopy (SEM). 
XRD measurements were performed on an Empyrean PANalytical X-ray diffractometer using Cu 
Kα1 (λ=1.54 Å) as radiation source, with a step size of 0.03° in the scanning range of 5º-70º. The 
obtained XRD patterns were analyzed using Highscore software for phase identification. SEM 
imaging was done using an FEI Quanta 3D FIB microscope operated at 5 kV accelerating voltage. 
This instrument was equipped with an EDAX detector which was used to identify the elements 
present in the sample. The sample was prepared by casting a drop of the aqueous product on the 
double-sided carbon tape attached to the sample holder. All the dried samples were sputtered with 
Pt for 4 min to make the sample conducive for the measurements. These nanoparticles were finally 
characterized for optical properties using Photoluminescence (PL) studies. An APTI QM-40 
spectrofluorometer with a PMT detector and a 75W xenon arc lamp as light source was employed 
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for PL measurements. The scans were performed with a band pass of 2 nm at a scanning rate of 4 
nm/s in the range of 450-650 nm upon respective constant UV excitation.   
2.2.3 Design and Fabrication of the Microfluidic Droplet Trapping Array 
The droplet microfluidic trapping array used in this work is similar in scope to one 
previously reported by Safabakhsh et al.[49] The geometry of the device was designed with Autocad 
software prior to fabrication. As seen in Figure 2.1.A, the device consisted of two layers: the 
bottom main flow channel and the top trapping array (Figure 2.1.B), each having a 40 µm height. 
The device had two inlet channels: one for carrier oil (750 μm in diameter) and one for cells/NPs 
(470 μm in diameter) which converge at a flow-focusing junction to encapsulate cells and NP in 
~180 pL discrete aqueous droplets in a continuous oil phase. Each inlet had a set of microfilters to 
prevent any solid residues from clogging the device. The essential component of the bottom layer 
(Figure 2.1.C), is the flow focusing junction where both the phases meet for the droplet formation. 
After droplet formation, they travel for ~700 µm across a narrow channel before widening and 
distributing through the bottom main layer. Serpentine channels were incorporated prior to the 
flow-focusing junctions to equalize the pressure for droplet formation at the junction. The 
flowrates of each phase play a critical role in the size of droplets. Here, flowrates of 230 µL and 
90 μL for the oil and aqueous phases were used to generate droplets of 70 µm diameter. The droplet 
trapping array (Figure 2.1.D, E) consisted of a 775-member grid of 70 μm diameter circles 
imprinted at a ~40 μm height into the PDMS, to trap the aqueous droplets. The micron scale 
channel height and immiscibility of the two phases force the droplets from the oil phase into the 
overhead traps. The oil flow was maintained continuously to avoid flushing-out of the trapped 
droplets after trapping. Vertical fins were incorporated into the trapping array to increase the 
residence time for the potential trapping of these droplets. An outlet port was incorporated at the 
end of the flow channel to collect the exit stream.   
 
 
Figure 2.1- Schematic of the microfluidic droplet trapping array. A) Top view of the device 
showing two inlets – one for carrier oil and one for cells and flow-focusing junction in the bottom 
layer; trapping array in the top layer. B) Side view illustration of the droplet trapping array C) 
Converging of the two fluids at a flow-focusing junction to generate pL-sized droplets. Bright field 




Figure 2.2 – Fabrication of the microfluidic droplet trapping array. A) Soft lithography was used 
to fabricate microfluidic patterns on a silicon wafer. B) PDMS replication followed by plasma 
bonding and Aquapel treatment was used to create a working microfluidic device 
The microfluidic devices were fabricated by a combination of soft lithography and PDMS 
replication. The first step was to create the fluidic patterns on a silicon wafer as shown in Figure 
2.2.A. The two-step process started with generating the bottom layer consisting of the fluidic 
channels using a photoresist polymer (SU-8-2025, Mirochem). The SU-8 was deposited on a clean 
silicon wafer and baked at 65°C for 15 minutes followed by a second bake at 95°C for 30 minutes. 
After cooling down, the wafer was exposed to UV light with 1.2 mW/cm power intensity for 50 
seconds using a photo mask to create the fluidic channels. The wafer was baked again at 95°C post 
UV exposure. Following this, a second layer of SU-8 was spun onto the silicon wafer followed by 
the same 65°C and 95°C baking steps. The wafer was manually aligned with a second photomask 
containing the overhead trapping array followed by UV exposure. Finally, the silicon wafer was 
developed with an SU-8 developer solution (Microchem). This step dissolved all of the uncross 
linked SU-8 to produce the microfluidic patterns. The wafer was hard baked at 150°C for 30 
minutes to increase wafer durability. After cooling down, the wafer was ready for PDMS (poly 
dimethyl siloxane) replication. PDMS base was mixed with curing agent (SLYGARD 184 silicone 
elastomer kit), in the ratio of 10:1 and degassed in a vacuum chamber to eliminate bubbles formed 
when mixing. This degassed PDMS mixture was poured on the fabricated wafer sitting in a petri 
dish and was baked for 6 hours at 65°C to cure. Once cured, the PDMS was peeled from the wafer 
and the replicas of these microfluidic devices were cut. The device inlet and outlet ports were 
punched using a micron-sized hole puncher (a blunted 23G x1 needle). Each PDMS replica was 
permanently bonded on a glass slide (Corning Glassware 75x25 mm) using a Harrick Plasma PDC-
32G basic plasma cleaner. The devices were left overnight to ensure proper bonding between the 
PDMS and the glass. The device channels were then made hydrophobic by Aquapel treatment. 
Aquapel treatment was essential to prevent channel wetting and the formation of uniform aqueous 
phase. Aquapel was manually injected into the device using a filtered syringe with excess Aquapel 
flushed out using Novec 7500 oil (3M). The channels were finally dried by blowing nitrogen and 
the resultant device as shown in Figure 2.2.B was ready to be used for on-chip experiments.  
 
2.2.4 Cell Culture 
MDA-MB-231 cells and RFP expressing MDA-MB-231 cells were a kind gift from Dr. 
Elizabeth Martin (LSU). GFP (Green Fluorescent Protein) expressing HeLa cells were a kind gift 
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from Dr. Nancy Allbritton (UNC). All cell lines were all maintained in T75 culture flasks. The 
MDA-MB-231 cells were cultured in DMEM – Dulbecco’s Modified Eagle Medium with 10% 
v/v fetal bovine serum (FBS, Seradigm), 1% MEM Essential Amino Acids (Quality Biological 
Inc.), 1% MEM Non-Essential Amino Acids (Quality Biological Inc.), 1 mM Sodium Pyruvate 
and 6 µL insulin/500 mL media. The HeLa cells were cultured in DMEM Media with 10% v/v 
Calf Bovine Serum. 10X Phosphate-Buffer Saline (PBS: 137 mM NaCl, 10 mM Na2HPO4, 27 mM 
KCl, and 1.75 mM KH2PO4 at pH 7.4) and trypsin (Trypsin-EDTA (0.05%) -Thermo Fisher 
Scientific) were used during the process of cell culture. 
2.2.5 Off-chip Viability Assay 
MDA-MB-231 cells were seeded at a density of 1 x 104 cells/mL in 12 well plates and 
allowed to incubate for 3 days. On the day of experiment, each well of the 12-well plate was 
washed with 1 mL of 1X PBS. 1 mL of a 10 mg/mL nanoparticle slurry in Extra Cellular Buffer 
(ECB: 20 mM HEPES, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2.6H2O, 1 mM CaCl2.2H2O, 5 mM 
D-Glucose at pH 7.4) was added to each well at one-hour intervals for a 12-hour time period. After 
the final time point, the NP slurry was aspirated. It should be noted that, after aspiration of NP 
slurry the cells were not washed with PBS to avoid removal of dead cells. 500 µL of reagent stain 
mixture (2.5 µM Calcein AM and 4 µM EthD-1 in 1X PBS) was added in each well and incubated 
for 20 mins and imaged for viability. Calcein AM and Ethidium Homodimer (EthD-1) are 
fluorescence cell viability stains that are based on the simultaneous determination of live and dead 
cells. Live cells are distinguished by the presence of intracellular esterase activity, determined by 
the enzymatic conversion of virtually non-fluorescent cell-permeant Calcein AM to the intensely 
fluorescent calcein. The polyanionic calcein is well retained within live cells producing an intense 
green fluorescence in live cells under λex = 485 nm and λem = 515 nm. EthD-1 enters only cells 
which have compromised membranes and undergoes a 40-fold increase in fluorescence upon 
binding with nucleic acids, thereby producing a bright red signal in dead cells under λex = 525 nm 
and λem = 590 nm and thus excluded by the intact plasma membrane of live cells. The experiment 
was imaged using a fluorescent DMi8 Inverted Microscope (Leica microsystems). FITC filter set 
(λex: 440-520 nm and λem = 497-557 nm) and Rhodamine filter set (λex: 536-556 nm and λem = 545-
625 nm) were used to excite and capture live/Calcein AM and dead/EthD-1 cells. 
2.2.6 Off-chip Fluorescent Microscopy 
Next the RE-doped NPs were evaluated for fluorescence using microscopy. A microscopy 
imaging chambers was made by binding Silicone O-rings (Ace glass) to microscopy cover slips 
(Corning 4x40 mm) using high vacuum grease (Dow Corning. The nanoparticle slurry was made 
by weighing and mixing the NP powder in ECB. 200 µL of this slurry was added to the imaging 
chambers and imaged using a fluorescent DMi8 Inverted Microscope (Leica microsystems). The 
following filter sets (Chroma Tech. Corp) were used for imaging the different nanoparticles: Eu3+ 
doped NP (λex: 370-420 nm and λem: 605-645 nm); Tb
3+ doped NP (λex: 325-355 nm and λem: 505-
565 nm);  
2.2.7 Microfluidic Droplet Tracking using RE-doped Nanoparticles 
NPs with different dopant concentrations (e.g., 2.5 and 5 mol% of X3+ in NaYF4) and 
different suspension concentrations (5-10 mg/mL) were encapsulated and trapped within ECB 
droplets without cells and imaged using a fluorescent DMi8 Inverted microscope (Leica 
microsystems). For cell and NP co-encapsulation experiments, the RE-doped nanoparticles were 
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co-encapsulated with cells (GFP HeLa cells or RFP MDA-MB-231 cells at a cell density of 6 x106 
cell/mL) in aqueous ECB droplets which were then isolated and imaged in the microfluidic droplet 
trapping array using a fluorescent DMi8 Inverted microscope (Leica microsystems). The aqueous 
phase was the NPs and cells in ECB; the oil phase was Novec 7500 oil with 0.2% Neat 008 fluoro-
surfactant (Ran Biotechnologies). The fluoro-surfactant was used to stabilize droplet formation 
and prevent droplet aggregation. To encapsulate cells with NP in droplets, 4.5 x 106 cells/mL were 
supplemented with an NP slurry of 5 mg/mL in ECB. To initiate droplet generation, Tygon tubing 
(Cole Palmer) was directly connected to syringes fixed on a dual infusion syringe pump (Harvard 
apparatus) and were inserted into the device inlet ports. Different flowrates of 230 µL/hr and 90 
µL/hr were used for the oil and aqueous phases. The device was set on the stage of a fluorescent 
DMi8 Inverted microscope (Leica microsystems).  
To determine if the RE-doped nanoparticles could be encapsulated in droplets with a 
population of cells exposed to a standard biochemical assay, a dead stain (Ethidium Homodimer) 
was selected. To ensure a population of dead cells MDA-MB-231 cells were binned into two 
groups. The first group (live) was resuspended in ECB and incubated at 37°C prior to 
encapsulation. The second group (dead) was incubated at 42° C for 1 hour in a heat block to kill 
all the cells. These populations of live and dead cells were mixed together with 4 µM EthD-1, 
incubated at 37°C for 15-20 minutes, and then injected into the device with the NP slurry.  
Qualitative Imaging: Fluorescent DMi8 Inverted microscopy (Leica microsystems) with a digital 
CMOS camera C11440 (Himamatsu Photonics K.K.) and software LASX version 3.3.0 were used 
to image and analyze these experiments.  The following excitation/emission filters (from Chroma 
Tech. Corp) were used: FITC filter set (λex: 440-520 nm and λem = 497-557 nm) for GFP; 
Rhodamine filter set (λex: 536-556 nm and λem = 545-625 nm) for RFP, EthD-1; Eu
3+ doped NP 
(λex: 370-420 nm and λem: 605-645 nm); and Tb
3+ doped NP (λex: 325-355 nm and λem: 505-565 
nm). 
Quantitative Analysis: Manual sorting was performed to categorize different droplet 
subpopulations and to obtain information on droplet trapping, single and multiple cell 
encapsulation, cell and NP co-encapsulation efficiencies. A sample analysis was done in triplicate. 
A manual line scan region of interest (ROI) was drawn across droplets containing both cells and 
NPs to quantify their fluorescent signal as well as their signal-to-noise ratio values (S: N). These 
values were normalized and was plotted using Origin (OriginLab Corp.).  
Normalized Fluorescent Signal = 
𝑋−µ
𝜎
                                                                                   [Eq 2.1]                                                               
Equation 2.1 was used to calculate a normalized fluorescence where X is the fluorescent signal of 
cell or NP, µ is the mean fluorescent signal, and σ is the standard deviation in the fluorescent 
signal. Statistical analysis of spectral independence was performed using analysis of variance 
(ANOVA) Hypotheses Tests or F-Tests using SAS Software. In order to statistically assess the 
spectral independence of NP from cells the normalized average of the S: N ratio of the NP obtained 
from the desired filter set was compared against its normalized average S: N ratio from other filter 
sets and was assessed by statistical t-test. The resulting p-values from these tests were reported. 
Similarly, spectral independence of cells (e.g, GFP-HeLa, RFP-MDA-MB-231, and MDA-MB-
231 cells stained with EthD-1) were also assessed by similar statistical analyses. A sample size of 




2.3 Results and Discussion 
2.3.1 Synthesis of Hexagonal β-NaYF4 Nanoparticles for Downconversion Applications 
The RE-doped nanoparticles were characterized using Scanning Electron Microscopy 
(SEM), X-Ray Diffraction (XRD) and Electron Dispersive X-Ray Spectroscopy (EDX) in order 
to ensure the correct structure, morphology and purity. All NP synthesis and characterization was 
performed by Khashayar R. Bajgiran, a collaborator on this project. The RE-doped luminescent 
nanoparticles were also successfully characterized using photoluminescence (PL) tests to confirm 
proper downconversion. The SEM results from Figure 2.3.A show the formation of uniform, 
monodisperse, hexagonal NaYF4 nanoparticles, of 400 nm in length and 150 nm in diameter. The 
diameter and length of these particles were controlled by varying the RE: citrate concentration up 
to 1:8 with a 1:1 ratio to produce nanoparticles with diameters of 150-500 nm and greater than 400 
nm long. Additionally, the crystal structure was characterized via X-Ray Diffraction (XRD). The 
XRD scan in Figure 2.3.B resulted in diffraction peaks which were indexed to the β-NaYF4 crystal 
structure (JCPDS #17-6069), indicating that no other impurity phase is formed. Electron-
dispersive X-Ray Spectroscopy (EDX) measurements confirmed that the particles were pure 
NaYF4.   
 
Figure 2.3- Characterization of RE-doped nanoparticles. The SEM image shows hexagonal 
nanoparticles roughly 150 nm in diameter and 400 nm in length. (B) The XRD scan is indexed to 
the β-NaYF4 crystal structure (JCPDS #17-6069) without the presence of contaminates based on 
(C) EDX fluorescence. (D) Photoluminescence of Eu3+ doped NaYF4 nanoparticles demonstrate 
the characteristic Eu emission peaks when excited with 397 nm light. 
 
As it can be seen from Figure 2.3.C, all crystals exhibited 𝐾𝛼 emission lines at 0.677 keV 
and 1.040 keV, along with 𝐿𝛼 emission line at 1.924 keV which were standard emission lines for 
Fluorine, Sodium, and Yttrium atoms respectively. Since the concentrations of RE dopants in the 
crystal structures were small, EDX results were magnified by a factor of 10 to illustrate the 
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presence of each dopant in the crystal lattice. The 𝐿𝛼 and 𝐿𝛽 emission lines at 5.817 and 6.456 
keV, 6.238 and 6.978 keV, 6.458 and 7.248 keV were assigned to Europium and Terbium, 
respectively. Si and Pt peaks were observed due to sample processing. Finally, downconversion 
photoluminescence tests were done to these RE-doped luminescent nanoparticles. As a result, 
room-temperature downconversion luminescence spectra of NaYF4:Ln
3+ (Ln3+: Eu3+ and Tb3+) 
were observed with the excitation wavelength of 397 nm for Eu3+ and 350 nm for Tb3+ (Figure 
2.3.D). For Eu3+, the 5D0 → 7F2 transition peak at 617 nm (red) was chosen for detection with 605-
645 nm window filter-set. Similarly, for Tb3+, the peaks at 543 nm (green) were chosen for 
detection in the 505-565 nm filter-sets respectively. Thus, RE doped nanoparticles with desired 
structure, morphology and optical properties were successfully synthesized and characterized. 
 
2.3.2 RE-doped Luminescent Nanoparticles are Biocompatible and Non-toxic in a Model 
Cancer Cell Line 
 
The biocompatibility of the RE-doped NPs was performed again the triple negative breast 
cancer cell line MDA-MB-231. The off-chip viability tests confirmed that the RE-doped 
nanoparticles were biologically inert to the cells even after an incubation period of 12 hours (Figure 
2.4). It was essential for the RE-doped phosphors to have no effect on the cellular viability if they 
were to be encapsulated with cancer cells in microfluidic droplets. Both live and dead MDA-MB-
231 cells were imaged in the presence of Eu3+ doped nanoparticles. As expected, the nanoparticles 
did not induce any cell death in the population of MDA-MB-231 cells over the course of 12-hour 
experiment as indicated by the lack of red cells in the right most column of Figure 2.4. A similar 
result was obtained in a control experiments in the absence of nanoparticles. This data showed that 
the RE-doped nanoparticles are non-toxic to cancer cells and can be successfully encapsulated 
with cancer cells in microfluidic droplets. 
 
Figure 2.4- The impact of the RE-doped luminescent nanoparticles on cellular viability. Eu3+-
doped NaYF4 nanoparticles were incubated with MDA-MB-231 cells at 37°C at 4 h (top row) and 
12 h (bottom row) followed by live/dead staining using Calcein AM (green, middle column) and 
EthD-1 (red, right column). Scale bar is 150 µm. 
15 
 
2.3.3 RE-doped Luminescent Nanoparticles can be Detected using Fluorescent Microscopy 
The downconversion process in the NPs was observed using fluorescent microscopy with 
a similar approach to that of the photoluminescence tests described above. First, the correct 
excitation and emission filters (Chroma Tech. Corp) were selected to collect he optimal excitation/ 
emission range of the RE-doped nanoparticles. The Eu3+ doped NP, when excited with a UV source 
(λex: 370-420 nm) luminesced in the red region which was captured by the emission filter (λem: 
605-645 nm). This can be seen in Figure 2.5.A and B, where the Eu3+ doped NP showed red 
luminescence upon UV excitation. Similarly, Tb3+ -doped NPs luminesced in the green regions 
upon UV excitation (data not shown). These results coincided with the previously discussed 
photoluminescence studies and validated that RE-doped nanoparticles can be visualized using 
fluorescent microscopy. 
 
Figure 2.5 - Microscopy image of Eu3+ -doped NP. Bright field A) and fluorescent B) images of 
the NP aggregate under 20X magnification. Transition peak 617 nm (red luminescence) of Eu3+ -
doped NP captured by emission filter λem: 605-645 nm when excited by UV source λex: 370-420 
nm. 
 
2.3.4 Successful Encapsulation of RE-doped Nanoparticles and Droplet Tracking in 
Microfluidic Trapping Array 
Once it was confirmed that the RE-doped NPs could be detected by fluorescent 
microscopy, the next step was to assess their ability to be used as droplet trackers in the 
microfluidic droplet trapping array. This was performed by conducting experiments encapsulating 
RE-doped nanoparticles in aqueous ECB droplets in the absence of cells. The NP-containing 
droplets were trapped and imaged with the findings from the Eu3+-doped NP encapsulation studies 
discussed here. As seen from Figure 2.6, stable droplets encapsulating nanoparticles were 
generated and trapped using the microfluidic device. Different NP suspension concentrations (5 
mg/mL and 10 mg/mL) were successfully encapsulated in the device. A 5 mg/mL NP slurry 
resulted in the nanoparticles forming small aggregates having a non-uniform distribution across 
the droplet. A NP slurry of 10 mg/mL showed a significant nanoparticle aggregation along the 
periphery of the droplets, unlike the suspension concentration of 5 mg/mL. Additionally, NPs with 
different dopant concentrations (Eu3+:2.5 mol% and 5 mol%) were used in nanoparticle 
encapsulation experiments (data not shown). However, the difference in dopant concentration did 
not have a significant difference in fluorescent intensity from NP within droplets (described in 




Figure 2.6 –RE-doped NPs encapsulated in aqueous droplets in a microfluidic device. Different 
concentrations of NPs were injected into the device: 5 mg/mL (top row) and 10 mg/mL (bottom 
row). The NPs formed small aggregates across the droplet for 5 mg/mL NP slurry but aggregated 
along the periphery of the droplet for 10 mg/mL suspension. Scale bar is 35 µm. 
 
Once NP encapsulation was confirmed in the droplet microfluidic device, the next step was 
to confirm their ability as droplet trackers. A potential application of the RE-doped nanoparticles 
was to track droplets containing single cancer cells. It is important to note that the NPs are not 
barcoding individual droplets (and hence individual cells), but are more useful to track different 
inlet conditions. For example, a population of cells challenged with a specific dose of a 
chemotherapeutic (e.g., concentration or number of drugs). To explore the ability of the RE-doped 
NPs as droplet trackers, cell and NP co-encapsulation experiments were performed. Eu3+-doped 
nanoparticles were co-encapsulated with GFP-expressing HeLa cells to confirm that the cells and 
NPs exhibited distinct, independent fluorescent spectra. As expected, there was no overlap in 
emission spectra between the Eu3+-doped NP and the GFP HeLa resulting in two separate, easily 
visualized fluorescent signals (Figure 2.7). Interestingly, sometimes the nanoparticles were 
observed to aggregate around the cells in addition to non-uniform distributions across the droplets. 
These results are shown in Figure 2.7 and were also successfully repeated with RFP-expressing 
MDA-MB-231 cells expressing red fluorescent protein (data not shown). Next, this analysis was 
extended to determine if the RE-doped nanoparticles could be encapsulated in droplets with a 
population of both live and dead cells. To accomplish this, the mixed population was stained with 
EthD-1 (red cells = dead) and co-encapsulated with Eu3+-doped nanoparticles in the microfluidic 
device. As seen in Figure 2.8, the microfluidic trapping array was easily able to separate and 
identify live and dead cells. In some cases, the NPs would aggregate on top of dead cells and which 
resulted in a slight ambiguity to distinguish a dead cell from within a layer of nanoparticle 
aggregate. However, the fact that the nanoparticles would aggregate at many different spots across 
droplets was used to address this issue. The nanoparticles that aggregated away from the dead cell 
were used to confirm the spectral independence of Eu3+-doped NP from EthD-1. Fortunately, this 
issue only occurred in ~1% of the cells. It was discovered that the Eu3+-doped NP did not show up 
in the filters that were used to capture Tb3+-doped NPs, highlighting the potential of RE-doped 




Figure 2.7 - 5 mg/mL Eu3+-doped NaY4 nanoparticles co-encapsulated with GFP-expressing HeLa 
cells. Brightfield (upper left), 492/514 nm excitation/emission (upper right), 395/620 nm 
excitation/emission (lower left), and overlay (lower right) images. * denotes NPs and # denotes 
GFP-HeLa cell across the droplet.  
 
 
Figure 2.8 – Spectral independence of EthD-1 (dead stain) with nanoparticles. A mixed population 
of live and dead MDA-MB-231 cells was co-encapsulated in aqueous droplets along with 5 mg/mL 
Eu3+-doped nanoparticles. Dead cells are shown in red due to EthD-1 uptake and live cells 
remained colorless. Brightfield (upper left) image. No overlap in emission spectra was observed 
between EthD-1 (upper right) nanoparticles (lower left). Overlay image (lower right) highlighting 
different subpopulations – magenta box showing droplet with just NP, red box showing dead cell 
with NP, green box showing live cell with NP. Note: Nanoparticles are depicted in magenta to 
distinguish from the dead stain (red).  
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2.3.5 Quantification and Confirmation of Spectral Independence between Biochemical 
Stains and Eu3+-doped Nanoparticles 
 
Up until now all of the reported results have been qualitatively evaluated by visual 
inspection of the cells and NPs within the aqueous droplets. In effort to confirm the signals 
observed are distinct and reproducible, quantitative analysis was performed with the cells and NPs 
across the different filter sets. 
Manual sorting to categorize different droplet sub-populations  
Single cells are distributed within the aqueous droplets following a Poisson distribution 
with a typical single cell encapsulation rate of ~40% of the droplets. Next, the distribution of both 
NPs and cells within the droplets was investigated to determine the statistics of how both species 
separated across the population of trapped droplets. Five scenarios were identified and assessed 
across the entire array: (1) droplets with nanoparticle aggregates, (2) droplets with cells, (3) 
droplets with NPs and a cell (distinct ROI), (4) droplets with NPs on top of cells (indistinct ROI), 
and (5) empty droplets. Such diverse droplet subpopulations were generated due to the random 
nature of how both species interact during droplet generation as a result of inability to control the 
presence of nanoparticles/cells within droplets, or to decide the position of nanoparticles/cells 
within droplets. A sorting analysis was performed to identify the percentages of each 
subpopulations in addition to identifying single/multiple cell encapsulation efficiency, NP tracking 
efficiency and also the ability to distinguish spectral features of NP and cells 
(fluorophore/fluorescent stain). A sample analysis from GFP HeLa cell and Eu3+ doped 
nanoparticle co-encapsulation experiments with a sample size of n=2200 droplets yields ~6% 
empty droplets, ~43% droplets with just NP and ~51% droplets with cells and NP (Figure 2.9). 
 
Figure 2.9 – Different subpopulations achieved within droplets during NP and cell co-
encapsulation experiments. A) Percentage of each sub-population (n = 2200 droplets) i) empty 
droplet ii) droplet with just NP iii) droplet with just cell iv) droplet with NP and cell v) droplet 
with NP around cells vi) droplet with multiple cells. B) Image of each of the five subpopulations 
described in (A) 
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Effect of dopant and suspension concentration in NP encapsulation experiments 
In order to identify optimal NP loading conditions within the aqueous droplets, several 
variables were evaluated including dopant concentration and NP slurry concentration. Results 
from Eu3+-doped NPs encapsulated in droplets are presented in Figures 2.10 to 2.12. First, it was 
discovered the dopant concentrations of 2.5 mol % and 5 mol % did not have a significant effect 
on NP fluorescent signal. Interestingly, these results did not conform with the photoluminescence 
test as shown in Figure 2.11. This could be due to the fact of exciting a single NP aggregate in a 
picoliter sized droplet in the microfluidic device provides a different environment when compared 
to exciting a highly concentrated NP slurry during off-chip photoluminescence tests. Next, the 
effect of NP slurry concentration was assessed in the aqueous droplets. As shown in Figure 2.12.A, 
B, the nanoparticles aggregated along the periphery of the droplet for a 10 mg/mL Eu3+ NP slurry. 
A comparison was made with an ECB control droplet with no NPs and a 5 mg/mL Eu3+ NP slurry 
(Figure 2.10) to confirm that the two peaks in Europium filter observed at the periphery of the 
droplet were due to the accumulation of NP along the interface of droplets. However, for a 10 
mg/mL NP suspension, the inability to control NP concentration within each droplet led to a highly 
variable system which resulted in inconsistency with NP accumulation across the droplet 
periphery. Thus, a 5 mg/mL NP suspension with a dopant concentration of 2.5 mol% was observed 
to be the optimal conditions to provide the desired fluorescent signal from the NPs. The average 
normalized S: N ratio value of NP from each of the fluorescent channels for the above cases are 
shown in Tables 2.1 and 2.2. A sample size of n=320 droplets was used for each case. These 
numerical values conformed with the graphical explanation and thus, showed the spectral 
independence of Eu3+ -doped NP from other filter sets used in this study. 
 
Figure 2.10 – Effect of dopant concentration on NP fluorescent signal in aqueous droplets A) 5 
mg/mL, 2.5 mol% Eu3+-doped NPs in ECB droplets. Line scan ROI across droplet showing the 
signal intensity from NP along the distance of the line. B) 5 mg/mL, 5 mol% Eu3+-doped NPs in 
ECB droplets and respective line scan showing the signal intensity from NP across the distance of 





Figure 2.11 – Downconversion photoluminescence of 5 mg/mL Eu3+-doped NPs and the effect of 
dopant (Eu) concentration in emission peak intensity. A) Excitation wavelength of 397 nm for Eu: 
X mol%-doped NaYF4. B) Higher intensity in emission peak of 5 mol% Eu (in red) over 2.5 mol% 
Eu (grey). 
 
Table 2.1- Effect of dopant concentration on NP fluorescent signal. Line scan ROI across droplets 
giving average normalized S: N ratio value of Eu3+ doped NPs. Analysis confirmed spectral 
independence of Eu3+-doped NPs with other filter sets used in this study. 
 
 
Figure 2.12 - Effect of NP slurry concentration on fluorescent signal and distribution. (A) Control 
ECB droplet alone with no NPs. Line scan across droplet showing no significant peaks denoting 
absence of NP inside droplet. B) Eu3+-doped NPs (10 mg/mL) encapsulated in ECB droplets. Line 
scan having two peaks confirming accumulation of NP along the interface. * denotes the NP and 
its corresponding signal intensity across the droplet. Data is representative of ~320 droplets. Scale 














NP 45-60 1.03 1.11 3.16 1.20 
Cell - - - - - 
Figure 
2.10.B 
NP 40-60 1.13 1.08 3.86 1.18 
Cell - - - - - 
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Table 2.2- Effect of Eu3+-doped NP slurry concentration on fluorescent signal. Average 
normalized S: N ratio value of Eu3+ doped NPs and their spectral independence with other filter 
sets used in this study. 











NP - 1.12 1.09 1.42 1.3 






1.26 1.04 4.63 1.05 
Cell - - - - - 
 
Eu3+ -doped NPs are spectrally independent from green fluorescent protein (GFP HeLa cell) 
In order to quantify the spectral independence of Eu3+-doped NP with GFP, Eu3+-doped 
NPs and GFP-expressing HeLa cells were co-encapsulation in the microfluidic device. A few 
example cases were considered as shown in Figure 2.13. As seen in Figure 2.13.A, a droplet 
containing a GFP-HeLa cell gave distinct signal from its filter. In Figure 2.13.B, a droplet 
containing both Eu3+-doped NPs and a GFP-HeLa cells at different positions resulted in 
distinguished signals in the respective filter sets. In case of Figure 2.13.C, the Eu3+-doped NPs 
formed a layer around the GFP-HeLa cells giving raise to overlapping signals at that ROI position. 
This occurred in ~1% of the total population. In some cases, despite this overlap, there was a NP 
aggregate elsewhere in the droplet giving rise to a small peak in the Europium filter set at a 
different ROI position clearly showing that the droplet was tracked by the Eu3+-doped NPs. Table 
2.3 shows the numerical correlation of these results in terms of the S: N ratio values. A sample 
size of n=35 droplets was used for each case. 
 
Table 2.3- Spectral independence of Eu3+ doped NP with green fluorescence protein (GFP). 
Average normalized S: N ratio value of Eu3+ doped NPs, GFP-HeLa cells and their spectral 














NP - - - - - 
Cell 50-70 6.54 1.21 1.01 1.69 
Figure 
2.13.B 
NP  37.5-52 1.18 1.05 5.56 1.15 











Figure 2.13 – Spectral independence of Eu3+-doped NPs compared to GFP-expressing HeLa cells 
A) GFP-HeLa cell encapsulated in ECB droplet without NPs. Line scan across droplet showing a 
significant signal from the cell. B) Eu3+-doped NPs co-encapsulated with a GFP-HeLa cell. Line 
scan having distinguished signals at different line ROI from respective filters confirm the presence 
of NPs and cell at different spots inside droplet. C) Example of NPs around a cell. The fluorescent 
signal from NPs and the GFP-HeLa cell was distinguished using the respective filters along the 
same line ROI denoting the presence of NP and GFP-HeLa cell at the same spot. * denotes NPs 
and # denotes GFP-HeLa cell and their corresponding signal intensities across the droplet. Scale 
bar is 35 µm. 
 
Eu3+ -doped NP is spectrally independent with red fluorescent protein (RFP MDA-MB-231 cell) 
A similar analysis was performed as described above but now with RFP-expressing MDA-
MB-231 cells to confirm the spectral independence of Eu3+-doped NP and RFP. Similar to the 
results discussed in the previous section, Figure 2.14 consists of an example droplet from each 
case. The RFP MDA-MB-231 cell gave a distinguished signal in its corresponding filter sets 
(Rhodamine) as shown in Figure 2.14.A. Cases like in Figure 2.14.B, where the cell and Eu3+-
doped NP aggregate were at different positions inside a droplet, led to distinct ROI positions 
contributing to clearly defined fluorescent signals. In some cases, the Eu3+-doped NP formed a 
layer around the cell which gave rise to distinct signals (Figure 2.14.C). The S: N ratio values for 
each of these cases corresponding to the respective fluorescent channels as shown in Table 2.4 
highlight the spectral independence of Eu3+-doped NPs from red fluorescent protein (RFP). A 
sample size of n=35 droplets was used for each case. 
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Table 2.4 - Spectral independence of Eu3+-doped NPs from red fluorescence protein (RFP). 
Average normalized S: N ratio value of Eu3+-doped NPs, RFP-expressing MDA-MB-231 cells and 
their spectral independence with their detection filters and other commonly used filter sets. 











NP - - - - - 
Cell 60-75 1.10 5.32 1.43 1.11 
Figure 
2.14.B 
NP 30-50 1.02 1.34 5.21 1.09 







1.19 1.03 5.98;5.81 1.36 
Cell 45-60 1.23 4.68 1.31 1.09 
 
 
Figure 2.14 - Spectral independence of Eu3+-doped NPs from RFP-expressing MDA-MB-231 
cells. A) A cell encapsulated in a droplet without NPs. Line scan across droplet showing a 
significant signal from the cell. B) Eu3+-doped NPs co-encapsulated with an RFP-MDA-MB-231 
cell. Line scan having distinguished signals at different line ROI from respective filters confirm 
the presence of NP and cell at different spots inside droplet. C) Instance of NPs aggregating around 
a cell. Distinguished signals from the NPs and the cell were observed from respective filters. * 
denotes NPs and # denotes RFP-expressing MDA-MB-231 cells and their corresponding signal 
intensities across the droplet. Scale bar is 35 µm. 
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Eu3+ -doped NP is spectrally independent with Ethidium Homodimer (dead cell)  
A similar analysis was then performed using the common dead stain Ethidium Homodimer. 
A population of live and dead MDA-MB-231 cells were stained with EthD-1 and co-encapsulated 
with Eu3+-doped NPs inside droplets. The resulting droplets consisted of 8 subpopulations: 
droplets with 1) just NPs 2) live cell(s), 3) dead cell(s) 4) live cell(s) with NPs (-distinct ROI), 5) 
dead cell(s) with NPs (distinct ROI), 6) live cell(s) with NPs (indistinct ROI), 7) dead cell(s) with 
NPs (indistinct ROI), and 8) a combination of live and dead cells inside the same droplet. The 
above cases are discussed in Figure 2.15, showing the ROI position of cell and NP with their 
corresponding fluorescent signals. The first five subpopulations are easy to quantify with distinct 
S: N ratio values from the cell or NPs (Figures 2.15.A, C). The live cells in subpopulation 6 would 
not contribute to any fluorescent signal due to the absence of EthD-1 uptake– (Figure 2.15.B). 
Thus, this subpopulation gives a distinct signal only from Eu3+-doped NPs. Droplets from case 7 
(Figure 2.15.D) with overlapping fluorescent signals from the cell and NPs (which contribute to 
about 1% of the total population) were ignored. Subpopulation 8 is a complex system having a 
combination of live and dead cells which might or might not have overlapping signals. Such 
systems were neglected from the analysis due to the inability to distinguish if the cell was alive or 
dead. The average normalized S: N ratio values of the above cases is shown in Table 2.5 describing 
the subpopulations with live and dead cells. Each table shows the spectral independence property 
of Eu3+-doped NP with EthD-1 and the ability to quantify data even with complex droplet 
subpopulations.  
 
Table 2.5 - Spectral independence of Eu3+ doped NP with live MDA-MB-231 cells (No EthD-1 
uptake) and dead MDA-MB-231 cells (EthD-1 uptake). No signal from live cells and fluorescent 
signal in rhodamine filter from dead cells; average normalized S: N ratio value of Eu3+ doped NP 
















NP - - - - - 





52-70 1.10 1.27 4.37 1.21 
Figure 
2.15.C 
NP 45-60 1.03 1.12 4.57 1.01 
Cell 14-30 1.12 5.23 1.17 1.05 
Figure 
2.15.D 
NP 37-50;75-90 1.12 1.17 3.28;7.03 1.16 





Figure 2.15 - Spectral independence of Eu3+-doped NP with EthD-1-stained cells. A) Live cell 
encapsulated in a droplet. Line scan across droplet showing absence of NP. B) Eu3+-doped NP co-
encapsulated with a live cell. Line scan having distinguished signal in Europium filter confirming 
the presence of NP. No signal from Rhodamine filter showing the presence of live cell due to its 
inability to intake EthD-1. C) Example of NPs aggregating around the cell with distinguished 
signals from NPs and the cell from their respective filters. D) NP around cell giving distinguished 
signals from respective filters along the same and different line ROI distance giving overlapping 
signals in the former case but distinct signals in the latter case. * denotes NPs and # denotes dead 




Statistical assessment of spectral independence of Eu3+-doped NPs using ANOVA F-Tests  
The average normalized S: N ratio values obtained for Eu3+-doped NPs, GFP-expressing 
HeLa cells, RFP-expressing MDA-MB-231 cells, and EthD-1-stained MDA-MB-231 cells from 
the above experiments were further analyzed to confirm the results were statistically significant to 
confirm spectral independence. Spectral independence data from each of the above discussed 
experiments were considered. ANOVA hypotheses tests considering null hypotheses and alternate 
hypotheses for different cases are shown in Tables 2.6, 2.7, 2.8. P-values greater than 0.05 favor 
the null hypotheses while p-values smaller than 0.05 rejects the null hypotheses favoring the 
alternate hypotheses. Thus, the resulting p-values from Tables 2.7, 2.8, 2.9 show strong evidence 
for the null hypotheses proving the rightness of the quantified spectral independence of Eu3+-doped 
NP with GFP, RFP and EthD-1. A sample size of n=35 droplets was used. Such statistical evidence 
was very useful when threshold values of average S: N values had to be fixed for automating this 
quantification (see Chapter 3).  
 
Table 2.6 – ANOVA F-statistics for analysis of threshold values of average normalized S:N ratio 
values of Eu3+-doped NP and GFP-expressing HeLa cells. Null hypotheses: 3<µ(S:N)<7.5; 
3<µ(S:N)<10; µ(S:N)<2.5 for respective cases. ‘µ(S:N)’ denotes mean normalized S:N ratio values (i.e. 
the average normalized S:N ratio values fall within the range). Alternate hypotheses: The average 
S: N ratio values do not fall within the given range. P value <0.05 rejects the null hypothesis in 
favor of the alternate, whereas larger p values fail to reject the null hypotheses. 
Cases 
Average normalized 
S:N ratio value (AU) 
Normalized S:N ratio value - 







4.34 (Europium filter) 







GFP - HeLa 
5.86 (FITC filter) 










1.43 0.35 µ(S:N)<2.5 >0.05 
Rhodamine  
filter 
0.98 0.45 µ(S:N)<2.5 >0.05 
 
Table 2.7 – ANOVA F-statistics for analysis of threshold values of average normalized S:N ratio 
values of Eu3+-doped NPs and RFP-expressing MDA-MB-231 cells. Null hypotheses: 
3<µ(S:N)<7.5; 3<µ(S:N)<10; µ(S:N)<2.5 for respective cases. ‘µ(S:N)’ denotes mean normalized S:N 
ratio values (i.e. the average normalized S:N ratio values fall within the range). Alternate 
hypotheses: The average S: N ratio values do not fall within the given range. P value <0.05 rejects 




S:N ratio value (AU) 
Normalized S:N ratio value 







4.34 (Europium filter) 











5.41 (Rhodamine filter) 










1.28 0.33 µ(S:N)<2.5 >0.05 
FITC 
filter 
1.11 0.42 µ(S:N)<2.5 >0.05 
 
Table 2.8 – ANOVA F-statistics for analysis of threshold values of average normalized S:N ratio 
values of Eu3+-doped NPs and dead MDA-MB-231 cells (EthD-1-stained). Null hypotheses: 
3<µ(S:N)<7.5; 3<µ(S:N)<10; µ(S:N)<2.5 for respective cases. ‘µ(S:N)’ denotes mean normalized S:N 
ratio values (i.e. the average normalized S:N ratio values fall within the range). Alternate 
hypotheses: The average S: N ratio values do not fall within the given range. P value <0.05 rejects 




S:N ratio value (AU) 
Normalized S:N ratio value - 







4.34 (Europium filter) 








6.41 (Rhodamine filter) 










1.63 0.37 µ(S:N)<2.5 >0.05 
FITC 
filter 
1.03 0.53 µ(S:N)<2.5 >0.05 
 
2.4 Conclusions 
The combination of tumor heterogeneity and molecularly-targeted therapeutics has led to 
a more personalized approach to medicine with the potential for individualized, combinatorial 
therapeutics. However, for these treatment protocols to be effective, clinicians need high-
throughput screening technologies capable of rapid and facile single cell analysis of an entire 
patient sample. Techniques that can perform ex vivo quantification on the efficacy of drug doses 
and combinations will greatly reduce the time between diagnosis and treatment of patients 
suffering from cancer. As one such technique, this work proposes a novel nanoparticle-
microfluidic platform capable of high-throughput single cell analysis across a population of cells 
challenged with different doses and combinations of chemotherapeutics. This was accomplished 
by implementing biologically inert, rare earth (RE)-doped luminescent nanoparticles in a 
microfluidic droplet trapping array to act as droplet trackers by visually isolating cancer cells 
challenged with a specific dose.  
Upon synthesis and spectral characterization, these RE-doped luminescent nanoparticles 
were successfully proven to be biologically benign to living cancer cells through a series of off-
chip viability tests. As a proof-of-concept, Eu3+-doped nanoparticles were successfully 
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encapsulated within droplets and a distinct emission spectrum in the red region was observed upon 
encapsulation. The effect of dopant concentration (Eu3+: 2.5 mol% and 5 mol%) and NP slurry 
concentration (5 mg/mL and 10 mg/mL) in NP encapsulation was analyzed to identify optimal 
experimental conditions in terms of fluorescent signal intensity. This successful demonstration of 
droplet tracking was further extended to track cells within droplets on a high-throughput droplet 
microfluidic platform. A series of successful droplet trapping experiments co-encapsulating Eu3+-
doped NPs and GFP-expressing HeLa cells/ RFP-expressing MDA-MB-231 cells/ EthD-1-stained 
dead MDA-MB-231 were performed. These experiments found that the RE-doped NP exhibited a 
differing emission spectrum than common fluorophores (GFP, RFP) and fluorescent stains (EthD-
1). As an example, the spectral independence property of Eu3+ doped NP was quantified by a series 
of line-scan ROI quantification and statistical analyses. These fluorescent signals from Eu3+ -doped 
NP, GFP, RFP and EthD-1 were thus normalized, tabulated and verified for spectral independence 
through a series of ANOVA-F-tests. As a result of this robust quantification and statistical 
analyses, the spectral independence of these RE-doped nanoparticles was well ascertained. These 
experimentation and analyses will be extended to Tb3+ doped NPs in the near future. Thus, this 
work has demonstrated an innovative way of implementing these biologically inert and spectrally 
independent RE- doped luminescent nanoparticles as droplet trackers on a high-throughput 
microfluidic droplet trapping platform. While the studies described here only look at a single input 
condition into the device, the system can easily be multiplexed by fabricating a three-, four-, or 
five-input microfluidic droplet trapping array. In this new multiplexed system, the RE-doped NPs 
can be used to visually distinguish different input conditions creating a platform to tandemly 
screening different combinations of drugs across a population of cells. A further strength of this 
system is that it is capable of performing both population-based and single-cell analysis of the 
cancer cells to identify distinct subpopulations of cells, including drug resistant ones.  
29 
 
3. AUTOMATED IMAGE ANALYSIS OF FLUORESCENT MICROSCOPY DATA 




Microscale technologies such as droplet microfluidics has garnered significant interest to 
facilitate high-throughput, single cell analysis of heterogeneous populations like tumor biopsies. 
The inclusion of downstream trapping arrays in these devices allow for facile collection and 
segregation of droplets containing both single cells and multiple cells. The increasing number of 
high-throughput technologies have created a need to develop computational tools capable of 
processing and quantifying the large amount of data collected from these high-throughput screens. 
Manual cell counting has been widely used; however, these results may be subjective and vary 
from person to person. This resulted from the lack of software support for these techniques which 
has made it difficult to apply open-source software packages with high-throughput technologies. 
Existing open-source software like ImageJ[25] (NIH) and CellProfiler[26] (Broad Institute) are only 
capable of counting the total number of cells in a defined region which is not suitable for 
intracellular quantification on a large scale such as microfluidic trapping array. Proprietary 
microarray software such as Quantarray (Packard BioChip Technologies, Billerica, MA, USA) 
and Genepix (Molecular Devices, Sunnyvale, CA, USA) allow users to define arrays individually 
on one image, but fail to recognize the arrays themselves automatically.[28] The goal of this work 
was to develop an algorithm to rapidly analyze images of fluorescent cells trapping in droplets 
collected in the microfluidic droplet trapping array that was capable of (i) automatically 
distinguishing droplets from cells, (ii) counting live/dead cells in each droplet, and (iii) quantifying 
variations in intracellular fluorescence due to cell permeable biosensor. As a proof of concept, the 
algorithm was used to quantify two different systems. The first system was to quantify the 
heterogeneous uptake of cell penetrating peptides across a population of cancer cells.   Cell 
penetrating peptides have emerged as powerful tools for delivering different types of bioactive 
cargoes into the cytosol of intact cells for therapeutic and sensing purposes. However, the uptake 
dynamics at the single cell level has never been assessed due the lack of available technologies. 
Here, the algorithm will be used to analyze data collected by Safabakhsh et al[49] on CPP uptake. 
Second, the algorithm will be used to distinguish between live and dead cells in a population of 
MDA-MB-231 cells. The strength of the algorithm will show its ability to distinguish between the 
cells, droplets and allow for facile counting of live and dead cells trapped in the droplets.   
 
The algorithm called FluoroCellTrack was developed using the Python 2.7.5 software 
language (Python Imaging Library, Python Software Foundation). The algorithm was designed to 
handle overlay images obtained using fluorescent microscopy which consisted of both bright field 
and fluorescence overlays. The advantage of using Python for this analysis was that, it is a high-
level, interpreted and general-purpose dynamic programming language which involves imperative 
and simple object-oriented functional programming unlike the complex MATLAB scripts. 
Moreover, the syntax in Python helps the programmers to code in a fewer steps as compared to 
C++ or Java.  The FluoroCellTrack algorithm was found to be able to (i) automatically identify 
individual cells from cell clusters, (ii) detect single or multiple cells within a single droplet, and 
(iii) quantify variations in intracellular fluorescence due to either CPP uptake or the incorporation 
of live/dead stains. FluoroCellTrack takes <1 min to count cells and <7 mins to quantify 
intracellular fluorescence, compared to ~60 min and ~20 h using manual analysis. The accuracy 
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of FluoroCellTrack was compared with manual counting of cells and found a difference in only 
~6 cells out of a total population of 320 cells leading to a 98% similarity between the two 
approaches coupled with a 19-fold increase in analysis speed over manual counting. This algorithm 
can potentially be used for dynamic cell viability studies, droplet tracking and biomarking 
technologies. 
3.2 Description of the Theory and Workflow used in the Development of the FluoroCellTrack 
Algorithm for Automated Image Analysis 
The details and methods describing the culturing of cell lines, the design and fabrication of 
the microfluidic droplet trapping array are described in Chapters 2.2.3, 2.2.4. First set of data was 
similar in scope to the results obtained from Chapter 2.3.4, where the mixed populations of live 
and dead triple negative MDA-MB-231 cells were treated with Calcein AM and EthD-1 followed 
by encapsulation into the aqueous droplets (without NP).  The working of Calcein AM and EthD-
1 are described in Chapter 2.2.5. Quantifying data from this experiment was useful as it was similar 
to quantifying a dynamic cell response (cell viability) on drug treatment protocols. The second set 
of data was from a new experiment involving single cell analysis of CPP uptake in HeLa cells. 
The same method was used for cellular encapsulation and analysis as those described for 
quantifying dead staining in cells discussed in Chapter 2.3.4. Further details on methods performed 
for CPP quantification can be found in Safabakhsh et. al.[49]  
 
Figure 3.1 - Schematic of the multi-step python algorithm. A series of steps describing droplet and 
cell template generation, template matching, thresholding leading to droplet and cell detection. A 
final masking step resulting in the detection of number of cells per droplet. 
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Once the data set of CPP uptake in a population of cells was collected, it was processed by 
the FluoroCellTrack algorithm. The workflow for this is summarized in Figure 3.1, which 
highlights the key steps needed to individually quantify viability in a high-throughput manner 
across all of the cells trapped within the droplets. Prior studies by Khademhosseini et al.[27] and 
Shusheng Bi et al.[48] were instrumental in the development of the FluoroCellTrack algorithm. For 
the analysis, overlay images (~75-80 images) from each encapsulation experiment obtained using 
fluorescent microscopy were used as input. These overlay images, which consisted of both 
brightfield and fluorescence overlays, were batch-fed into the algorithm for analysis. The imaging 
features of this multi-step python algorithm such as droplet detection and cell detection are 
described for an example image (i of Figure 3.1) in this section. 
Droplet detection 
The overlay image as shown in (i) of Figure 3.1, had information about droplets (in 
brightfield) and cells (fluorescent red for dead cells, fluorescent green for live cells). This input 
overlay image was subjected to thresholding to enhance the dark features in the brightfield channel 
(e.g., the droplet outline) as a result of which, the outlines of droplets were highlighted to give 
image (step ii) of Figure 3.1, which was given a name D. After this step, template matching was 
performed to detect droplets. To do this, a droplet template (step v of Figure 3.1) was generated as 
a starting point. This droplet template was given a name, dw. Droplet template matching was done 
by convolving the droplet template dw with the initial thresholded image D to generate a droplet 
center correlation map Cd as shown in Eq 3.1. Template matching is a process where a template 
defined by the user (user-defined template) slides over the image pixel by pixel to find the objects 
in the image that are most similar to the template. 
Cd=D*dw                                                                                                                                                                     [Eq 3.1] 
The brighter pixels in this droplet center correlation map depicted the highly correlated points 
which were most likely to be the droplet centers. To precisely locate the droplet centers and remove 
the false positives, the local maxima in the droplet center correlation map were found using Eq 3.2 
to give droplet local maxima image Ld (image not shown) as shown below: 
Ld=l(Cd,Wd)                     [Eq 3.2] 
where l is a smoothing function done to the droplet center correlation map Cd to locate the local 
maxima of droplet centers with Wd as the window size used to search for the local maxima. Smaller 
window sizes were used for more precise local maxima location. This local maxima image Ld was 
further thresholded to generate the droplet center image Md (step vii of Figure 3.1) as shown in Eq 
3.3. 
Md=T(Ld,τd)                                                                                                                             [Eq 3.3] 
where T is the thresholding function used to generate the droplet center image Md containing the 
thresholded local maxima of droplet centers with values greater than the threshold value τd. This 
threshold value τd was selected appropriately to minimize misdetections and false positives. As a 
final step, droplet circles were drawn using the previously obtained droplet center image Md and 
known diameter range of 65-75 pixels. This range of droplet diameter was picked due to the slight 
variability seen in droplet sizes obtained after encapsulation experiments. For example, the input 
image in (step i) of Figure 3.1 had a resolution of 679 pixels (length) x 376 pixels (width), with 
droplet diameter of 70 pixels, as a result of which the final droplet map was generated as shown in 
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(step x) of Figure 3.1. This final step was elaborately used for cell detection which is described in 
the following paragraphs. 
Live/dead cell detection 
Cell detection consisted of similar steps explained in the previous section like template 
generation, template matching, center localization and thresholding. In addition to this, one final 
step was added to count the number of cells within each droplet. This live/dead cell detection 
algorithm is described using an example image (step i of Figure 3.1) in this section. As a starting 
point, the overlay image as shown in (step i) of Figure 3.1, which had information about droplets 
(in brightfield) and cells (fluorescent red for dead cells, fluorescent green for live cells) was used 
as an input. This input overlay image was a color image and it was used as an advantage to be split 
into red, green, blue (RGB) channels. As a result of this channel splitting, G and R were obtained 
as resultant images: G is the grayscale image of green channel representing live cells (step iii of 
Figure 3.1) and R is the grayscale image of red channel representing dead cells (step iv of Figure 
3.1). After this step, template matching was performed to detect cells. To do this, a cell template 
(step vi of Figure 3.1) was generated by the user. This cell template was given a name, cg/r. Cell 
template matching was done by convolving the cell template cg/r with the grayscale green and red 
channel images G and R, to generate live and dead cell center correlation maps Cg and Cr as shown 
in Eq 3.4.  
Cg and Cr = (G and R) *cg/r                                                                                                                                                     [Eq 3.4] 
The brighter pixels in these center correlation maps depicted the highly correlated points which 
were most likely to be the live and dead cell centers. To locate the cell centers and remove the 
false positives, the local maxima in the live and dead correlation maps were found using Eq 3.5 to 
give the live cell and dead cell local maxima images Lg and Lr (images not shown) as shown below: 
Lg and Lr = l(Cg and Cr, Wg/r)                                                                                                [Eq 3.5] 
where l is a smoothing function done to the live and dead center correlation maps Cg and Cr to 
locate the local maxima of live/dead cell centers with Wg/r as the window size used to search for 
the local maxima. Smaller window sizes were used for more precise local maxima location. These 
local maxima images Lg and Lr were further thresholded to generate the live and dead cell center 
images Mg and Mr (steps viii and ix of Figure 3.1) as shown in Eq 3.6. 
Mg and Mr=T(Lg and Lr, τg/r)                                                                                                    [Eq 3.6] 
where T is the thresholding function used to generate the final live and dead cell center images Mg 
and Mr containing the thresholded local maxima of cell centers with values greater than the 
threshold value τg/r. This threshold value τg/r was selected appropriately to minimize misdetections 
and false positives. Such a thresholding step helped in identifying individual cells in clusters. One 
final step was added here in order to count the number of live and dead cells within each droplet. 
For this, the final droplet map obtained as shown in (step x) of Figure 3.1 was masked individually 
over the final live and dead cell center images (steps viii and ix of Figure 3.1) to count the number 
of live and dead cells within each droplet. While masking the droplet map on a combined live/dead 
cell center images, gives information on single/multiple cell encapsulation count as shown in (step 
xi) of Figure 3.1. For example, by defining the droplet diameter range and masking the combined 
live/dead cell center maps, if two cell centers were detected within a droplet boundary, then it 
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would be considered as two cells per droplet. The quantified results of cell viability count and cell 
encapsulation count were exported separately to excel sheets for further analysis. 
Intercellular fluorescence level detection 
The algorithm was extended to quantify the heterogeneous uptake of cell penetrating 
peptides across a population of cancer cells. These cell penetrating peptides have emerged as 
powerful tools for delivering different types of bioactive cargoes into the cytosol of intact cells for 
therapeutic and sensing purposes, but the uptake dynamics at the single cell level has never been 
assessed due the lack of available technologies. Data collected by Safabakhsh et al[49] on CPP 
uptake was used for quantification, where the cell permeability of secondary structured β-hairpin 
cell penetrating peptides like RWRWR [Ac-RWVRVpGO(FAM)WIRQNH2], OWRWR [Ac-
OWVRVpGO(FAM)WIRQNH2] was compared with that of commercially available fluorescent 
peptides (Arginine and TAT) in terms of fluorescent intensity in single cancer cells by using the 
droplet microfluidic array. The fluorescent signal was due to the FAM tag attached to the peptide 
and this fluorescent intensity was measured using a fluorescent microscopy FITC with excitation 
and emission range of 490 nm and 535 nm. This CPP uptake was examined in model cancer cells 
including cervical cancer-derived HeLa cells, multiple myeloma-derived OPM2 cells.  The 
fluorescent microscopy data (~75 to 80 images) from each encapsulation experiment consisting 
information of varying fluorescent intensity from cells (corresponding to the varying cell 
permeability of different peptides) was quantifying using FluoroCellTrack as shown in Figure 3.2.  
 
Figure 3.2 - Schematic of the Python algorithm to quantify cell data. Brightfield and fluorescent 
images were input into the algorithm to define droplets and cells followed by template matching 
to identify single cells and measure cellular fluorescence 
Here, the fluorescent intensity quantification of an example image from a cell permeability 
and encapsulation experiment of 10 µM Arginine in single HeLa cells is described. As a starting 
point, the overlay image as shown in (step i) of Figure 3.2, which had information about droplets 
(in brightfield) and cells (fluorescent green for peptide uptake) was used as an input. The steps 
described in droplet detection were used to detect droplets. For cell detection, the steps described 
in live/dead cell detection were used. However, it is to be noted here that, after splitting the overlay 
image, only the green channel produced information corresponding to the fluorescent peptide 
uptake within cells (step ii in Figure 3.2). This was due to the fact that the FAM tag of these CPPs 
upon entering the cells emitted in the green region. After a series of cell template generation and 
cell template matching to detect cells, a step was included here to generate regions of interest 
(ROI’s) around the detected cell blobs as shown in (step iii) of Figure 3.2. Upon generation of 
ROI’s around the cells, maximum and mean pixel intensity values within each ROI, corresponding 
to the maximum and minimum fluorescent intensity were generated. These quantified values lied 
in the range of 0-255: 0 meaning no fluorescence (no CPP uptake) with 255 denoting maximum 
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fluorescence (maximum CPP uptake). Appropriate threshold values were used during this step to 
clearly eliminate false positives such as high background or false signal from peptide debris. In 
addition to the above-mentioned quantification of fluorescent intensities, areas of these ROI’s were 
detected and appropriately thresholded to eliminate false positives by distinguishing cells from 
debris. For example, a typical HeLa cell in each permeability and encapsulation experiment had a 
diameter of 20 pixels (corresponding to 20 microns). This was used as an advantage to eliminate 
several peptide debris which had diameters less than 20 pixels, thus eliminating false signals. The 
quantified fluorescent intensities with respective ROI area were finally exported to excel for 
further data analysis.  
3.3 Results and Discussion 
Successful quantification of cell count and viability in single and multiple cells using 
FluoroCellTrack 
The data obtained from the live/dead experiments described in Chapter 2.3.4 was 
quantified here using the microfluidic device and the FluoroCellTrack algorithm. The difference 
here was that, the mixed subpopulation of live and dead triple negative MDA-MB-231 cells were 
treated with both Calcein AM and EthD-1 prior to encapsulation within the droplets (without NP). 
Quantifying data from this experiment gave information about the number of live cells, the number 
of dead cells and the single vs. multiple cell encapsulation efficiencies.  
 
Figure 3.3 – Quantification of cell viability and single/multiple cell per droplet information. 
Overlay image (A) of brightfield and fluorescent (red and green) channels was used an input to be 
quantified by FluoroCellTrack through a series of droplet, cell detection and masking steps to 
detect single/multiple live and dead cells within droplets (B) 
 
The overlay images (~76 images) from the live/dead staining and encapsulation experiment 
of MDA-MB-231 cells were successfully quantified with the algorithm. For the sake of brevity, 
this section will discuss one representative image from this data set. As seen in Figure 3.3, the 
input overlay image was successfully quantified for the number of live and dead cells along with 
the total single cell count.  The droplet and cell detection steps as described in Chapter 3.2 were 
successfully able to detect droplets and cells. Further, defining droplet boundaries and masking of 
these droplet circles over the detected cells successfully gave the single/multiple live and dead cell 
count. The example excel data that was exported after quantification of this Figure 3.3.A is shown 
in Table 3.1. 
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Table 3.1 – Quantification of cell count and viability data of single/multiple cell encapsulation 
No. of droplets with single cells - 2 
No. of droplets with multiple cells - 1 
Droplet No. of live cells No. of dead cells Total cells 
1 - - - 
2 - - - 
3 - 1 1 
4 1 - 1 
5 1 2 3 
6 - - - 
7 - - - 
 
Quantification of intercellular fluorescence intensity representative of CPP uptake using 
FluoroCellTrack 
Permeability of several cell penetrating peptides like RWRWR, OWRWR, Arginine and 
TAT were quantified based on fluorescent intensity using this algorithm. The resultant 
quantification of one example image (out of 79 images) from an encapsulation experiment of 10 
µM Arginine in single HeLa cells is discussed here. As a result of this quantification, the 
permeability of the peptide Arginine was measured across a population of HeLa cells based on 
fluorescent intensity. The droplets and cells were successfully detected using the initial droplet 
and cell detection steps. After this step, ROI’s were successfully generated around the detected 
cells as shown in Figure 3.4. The maximum and mean fluorescent intensity values (in the range of 
0-255) of these ROI’s of detected cell blobs were successfully quantified. Moreover, these ROI’s 
were utilized to successfully distinguish cells from debris which eliminated false positive signals 
from peptide and cellular debris. The example data output file from quantification of Figure 3.4.A 
is shown in Table 3.2. For further data analysis, these quantified fluorescent intensity values were 
compared to background to give normalized S: N values. The quantified data of all the 79 images 
from this 10µM arginine uptake experiment is given in Table A.1 in Appendix. 
 
 
Figure 3.4 – Quantification of 10 µM arginine uptake in HeLa cells based on fluorescent intensity. 
Overlay image of brightfield and fluorescent (green) channel (A) was used as input to be quantified 
by FluorCellTrack through a series of droplet, cell detection and ROI generation to identify cells 




Table 3.2 – Quantification of 10 µM arginine uptake in HeLa cells based on fluorescent intensity 
No. of droplets with single cells - 4 




Max. fluorescent intensity 
(pixel) 
Mean fluorescent intensity 
(pixel) 
ROI1 681.50 243.78 200.40 
ROI2 542.81 250.42 213.08 
ROI3 904.26 213.84 209.36 
ROI4 1008.41 232.02 212.68 
 
Comparison between manual cell counting and FluoroCellTrack  
To compare the automated counting results with the manual ones, all 76 images (step i of 
Figure 3.1) from the previously explained live/dead staining experiment of MDA-M-231 cells 
were subjected to manual and automated quantification. The data was compared for droplet 
trapping efficiency, single/multiple cell encapsulation, empty droplets and live/dead cell count. As 
depicted in Figure 3.5, the graphs representing automated and manual counting are almost 
identical, which shows that the two counting approaches are analogous to each other. However, 
there was a difference ~ of 6 to 7 multiple cells which were considered as single cells out of a 
population of ~180 cells, during automated quantification. This was due to the fact that despite 
precise thresholding, single cells could be shadowed within multiple cell clusters across the 
trapping array.  Such false positives were of very negligible fractions and thus were eventually 
neglected. Further, the analysis speeds of automated and manual counting were compared. 
FluoroCellTrack took <1 min to count cells and <10 mins to quantify intracellular fluorescence 
intensity on a typical 2.4 GHz processor. The process time of 10 mins consisted of the time 
fractions spent on droplet, cell segmentation and detection, cell counting and fluorescence intensity 
measurements. This was superior to the ~60 min cell counting and ~20 h of fluorescence 
quantification using manual analysis. This algorithm had 98% similarity with manual counting and 
a 19-fold increase in analysis speed.  
 






The multistep Python algorithm, FluoroCellTrack was developed to process and analyze 
hundreds of microscope images collected during experimentation. The algorithm had several 
distinct features like automatic detection of droplet subpopulations such as empty droplets, single 
or multiple cells inside droplets, etc. The proposed algorithm was successfully implemented in two 
different systems: (i) live/dead subpopulation studies to understand cell viability and count the 
number of single/multiple cells within each droplet, (ii) quantification of permeability of different 
CPPs in single cells based on fluorescent intensity. This algorithm had well-defined and precise 
steps to eliminate false positives such as peptide and PDMS debris across trapping array. Manual 
control analyses conformed with the Python algorithm with a difference of just about ~6 to 7 cells 
(98% similarity). Moreover, this automated image analysis took about <1 min to count all the cells 
trapped in the array and <10 min to quantify the fluorescence intensity across the entire population 
of cells, proving it to be a powerful tool for microscopy data analysis. This was far superior to the 
~60 min cell counting and ~20 h of fluorescence quantification using manual analysis. Thus, the 
proposed algorithm could automatically identify individual cells from clusters, count single or 
multiple live/dead cells per droplet and thus can potentially be used for quantifying dynamic cell 
























Molecularly-targeted therapeutics and personalized medicine have dramatically increased 
the prognosis of patients suffering from cancer. However, tumor heterogeneity has limited the 
success of single drug treatment which led to the introduction of multiple therapeutic 
combinations. As such, multiple therapeutic combinations have required the development of new 
analytical methods capable of multiplexed high-throughput screening (HTS) technologies capable 
of examining both concentration and number of therapeutics. Droplet microfluidic devices have 
garnered significant interest to facilitate high-throughput, single cell analysis. One limitation of 
droplet generators is their ability to only assess a single input conditions like concentration or 
number of drugs. To address this limitation, rare earth (RE)-doped nanoparticles were coupled 
with a microfluidic droplet trapping array as a novel approach at droplet tracking to visually assess 
different input conditions into the device such as drug doses and combinations in the droplets. The 
β-hexagonal NaYF4 nanoparticles were doped with rare-earth emitters (Eu
3+ and Tb3+) which have 
a luminescence emission spectrum in the red and green region upon UV excitation. An advantage 
of the RE-doped nanoparticles is that their excitation and emission spectra do not overlap with 
standard fluorophores thus allowing for both droplet tracking and quantification of cell viability 
or enzyme activity. This spectral independence was observed in (i) GFP-expressing HeLa cell, (ii) 
RFP-expressing MDA-MB-231 cells, and (iii) pre-killed MDA-MB-231 cells stained with 
ethidium homodimer-1. Moreover, the RE-doped nanoparticles were confirmed to be biologically 
inert. Finally, a Python algorithm was developed to automatically distinguish droplets from cells, 
count cells in each droplet, and quantify cell viability to facilitate the single cell analysis in a high-
throughput manner. Thus, this work established the foundation for future applications using this 
technique in multiplexed droplet tracking to understand tumor heterogeneity through 
combinatorial therapies. The applications for this algorithm are numerous including fluorescence 
quantification, droplet tracking, and biomarker detection. 
 
4.2 Conclusions  
 
The droplet microfluidic trapping array described in this thesis is similar in design to one 
previously reported by Safabakhsh et al[49] described in Section 2.2.3. This device was successfully 
tested for its potential to isolate and trap single cancer cells in a high-throughput manner. To extend 
the application of this droplet microfluidic device in droplet tracking, a library of RE-doped β-
NaYF4 luminescent nanoparticles was synthesized by a hydrothermal process. These nanoparticles 
were further successfully characterized for structure, morphology and optical properties using 
Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), Energy-dispersive X-ray 
spectroscopy and Photoluminescence tests (PL). As observed in Figure 2.3, the SEM analysis 
showed hexagonal nanoparticles roughly 150 nm in diameter and 400 nm in length. The XRD scan 
and EDX fluorescence resulted in hexagonal β-NaYF4 crystal structures without the presence of 
contaminates. Photoluminescence of Eu3+ and Tb3+ doped NaYF4 nanoparticles demonstrated the 
characteristic red (for Europium) and green (for Terbium) emission peaks when excited with UV 
light. Further from Figure 2.4, it was seen that these nanoparticles were biologically inert in the 
triple negative breast cancer cell line MDA-MB-231 for a period of 12 h indicating their ability to 
be used on-chip with biological systems for long-term dynamic experiments. The novelty of this 
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work lies in the usage of RE-doped nanoparticles in fluorescent microscopy. As a proof-of-
concept, Eu3+-doped nanoparticles were successfully encapsulated within droplets and a distinct 
emission spectrum in the red region was observed upon encapsulation (Figure 2.6). The effect of 
dopant concentration (Eu3+: 2.5 mol% and 5 mol%) and NP slurry concentration (5 mg/mL and 10 
mg/mL) in NP encapsulation was analyzed (Tables 2.1 and 2.2) to identify optimal experimental 
conditions in terms of fluorescent signal intensity. This successful demonstration of droplet 
tracking was further extended to track cells within droplets on a high-throughput droplet 
microfluidic platform. A series of successful droplet trapping experiments co-encapsulating Eu3+-
doped NPs and GFP-expressing HeLa cells/ RFP-expressing MDA-MB-231 cells/ EthD-1-stained 
dead MDA-MB-231 were performed as shown in Figures 2.7 and 2.8. These experiments found 
that the RE-doped NP exhibited a differing emission spectrum than common fluorophores (GFP, 
RFP) and fluorescent stains (EthD-1). As an example, the spectral independence property of Eu3+ 
doped NP was quantified by a series of line-scan region of interest (ROI) quantification and 
statistical analyses (Tables 2.3 to 2.5). The fluorescent signals from Eu3+-doped NPs, GFP-
expressing cells, RFP-expressing cells and EthD-1-stained cells were normalized, tabulated and 
verified for spectral independence through a series of ANOVA-F-tests as shown in Tables 2.7 to 
2.9. As a result of this robust quantification and statistical analyses, the spectral independence of 
these RE-doped nanoparticles was well ascertained. The overall high-throughput of these 
experiments were further increased by automating the image analysis. To account for the highly 
subjective and laborious manual counting, a multistep Python algorithm (Figures 3.1, 3.2) 
involving (i) droplet and cell template matching, (ii) cell center mapping, and (iii) local maxima 
and thresholding was developed to quantify droplet trapping efficiency, cell encapsulation 
efficiency, cell viability, and intracellular fluorescence intensity. This automated analysis was 
found to be accurate with manual counting of cells, with a difference of just ~2% coupled with a 
decrease in analysis time of <10 minutes over 20 hours of manual analysis.  
 
4.3 Future Work 
 
The goal of the future work is to increase the overall throughput of the combined 
nanoparticle-microfluidic approach by expanding upon the capabilities of the microfluidic droplet 
trapping array and the RE-doped nanoparticles. The studies described in this work looked at a 
single input condition into the microfluidic device; however, the system can easily be multiplexed 
by fabricating three-, four-, or five-input microfluidic droplet trapping arrays for increased 
throughput. The next step is to incorporate two additional flow focusing junctions into the 
microfluidic device to allow for simultaneous generation and trapping of aqueous droplets from 
three different inputs. This multiplex platform will be extended to screen different combinations 
of drugs across a population of cells. For this, the three distinct types of RE-doped nanoparticles 
(europium doped NPs along with terbium and dysprosium doped NPs) will be used. The distinct 
emission spectra of Eu3+-doped NPs in the red spectrum, Tb3+-doped NPs in the green spectrum, 
and Dy3+-doped NPs in the blue spectrum will be utilized to track and visually distinguish cells 
within aqueous droplets and finally allow for evaluation of three different treatment protocols in 
the same device (Figure 4.1).The dysprosium doped nanoparticles along with europium and 
terbium doped nanoparticles will be characterized for the correct structure, morphology, 
biocompatibility and downconversion application in fluorescent microscopy as described in 
Chapter 2.  Terbium and dysprosium nanoparticles will be individually co-encapsulated with 
model cancer cells like GFP HeLa cells, RFP MDA-MB-231 cells, dead MDA-MB-231 cells to 
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test their potential as droplet trackers (similar to Section 2.3.4). Their spectral independence with 
the commonly found fluorophores and fluorescent stains like GFP, RFP and ethidium homodimer 
will further be quantified and statistically analyzed as described in Section 2.3.5. Upon successful 
characterization of terbium and dysprosium for on-chip droplet tracking, the three distinct RE-
doped NPs will be incorporated into the three-input microfluidic device to encapsulate, trap and 
visually distinguish three subpopulations of cells. Further, multiple myeloma OPM2 cells will be 
challenged with three different orders of magnitude of the proteasome inhibitor bortezomib (1, 10, 
and 100 nM) and will be monitored across the high-throughput multi-input droplet tracking system 
to characterize drug efficacy and the dynamic response of cancer cells to multiple therapeutics, 
potentially identifying drug resistant cells. The automated image analysis described in Chapter 3 
will be utilized to quantify the results for the multiplexed NP-cell co-encapsulation experiments. 
Such a multiplexed system involves three distinct nanoparticles tracking three different treatment 
protocols in the form of cell viability. For this, the microscopy images from these multiplexed 
experiments will be processed to assign different colors for different species such as: red color for 
dead cell, cyan color for terbium nanoparticle, magenta color for europium nanoparticle and yellow 
color for dysprosium nanoparticle. The initial overlay microscopy images will be split into Red, 
Green, Blue channels (R channel giving information about dead cells), and Cyan, Magenta, 
Yellow, Black channels (C, M, Y, K channels) to give information about the presence of respective 
nanoparticles in droplets. These images will be used to (i) detect NP tracking efficiency, (ii) cell 
viability within the droplet, and (iii) cell and nanoparticle template matching. Droplet, cell, and 
NP cluster center correlation maps will be obtained after performing local maxima and 
thresholding steps similar to Section 3.2. Thus, overlapping the resultant center maps will give 
information on three distinct subpopulations based on cell response (viability) to different drug 
treatment protocols.  
 
 
Figure 4.1 – Schematic of the multi-input droplet microfluidic trapping array shown from the top. 
Graphic depicts Eu3+-doped (red), Dy3+-doped (blue), and Tb3+-doped (green) nanoparticles 
encapsulated with cells treated with different doses of chemotherapeutics. Droplets will be isolated 
in a trapping array downstream of the three junctions (dashed box). Grey is PDMS and yellow is 
the carrier oil. 
 
Moreover, this novel nanoparticle-microfluidic platform will be further extended to 
understand the efficacy of molecularly-targeted therapeutics by precisely quantifying the enzyme 
activity of critical oncogenic pathway of ubiquitin proteasome system (UPS) in model cancer cells. 
Proteasome and deubiquitinating enzymes (DUBs) are the primary targets from UPS due to the 
clinical success of proteasome inhibitors and recent findings confirming the role of DUBs in 
multiple myeloma cells developing a resistance to these proteasome inhibitors.  The quantification 
of intracellular enzyme activity in intact single cells across a population of cells like a liquid biopsy 
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would be beneficial to determine how patients respond to proteasome-targeted therapies, and to 
identify distinct subpopulations of drug-resistant cells in a heterogeneous sample. This will be 
achieved by developing a new method to directly measure enzyme activity in intact single cells 
across a heterogeneous population. This will be accomplished by developing unique fluorescent 
proteasome reporters that are long-lived, cell permeable, and enzyme-specific that incorporate a 
primary degron (peptide motif that specifies substrate recognition by E3 ubiquitin ligases) that is 
ubiquitinated in cells and also functions as a cell penetrating peptide. The substrate is a β-hairpin 
‘protectide’ sequence that will be incorporated into a novel fluorescence resonance energy transfer 
(FRET) reporter to directly quantify proteasome activity in intact cells. This novel proteasome 
reporter will be coupled with a novel DUB reporter developed by our research group to achieve 
multiplexed detection of two enzymatic targets. To achieve high throughput screening, the reporter 
will be incorporated in the droplet microfluidic trapping array capable of encapsulating and 
isolating single cells followed by dynamic quantification of intracellular enzyme activity. This 
technique will incorporate the rare-earth (RE)-doped luminescent nanoparticles in the multiplexed 
droplet microfluidic device for droplet tracking to correspond to different input conditions to 
increase the overall throughput of the system. The throughput will further be increased by 
automating the measurement of heterogeneous enzyme activity in single cells by quantifying the 
varying fluorescent intensity across the population. This bioanalytical tool will account for the 
significant heterogeneity associated with tumor biopsies and identifies distinct subpopulations of 
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Table A.1 – Heterogenous fluorescence intensity of 10 µM Arginine uptake in HeLa cells. 
Quantified data giving information on single/multiple cell encapsulation. Each ROI represents 
HeLa cells with its corresponding fluorescence intensity 
Single cell count 58 
Multiple cell count 13 
ROI FLUORESCENCE INTENSITY (AU) NOISE (AU) 
ROI1 178.83 9.77 
ROI2 212.49 9.77 
ROI3 169.13 9.77 
ROI4 153.02 8.2 
ROI5 204.57 8.2 
ROI6 174.32 8.2 
ROI7 100.34 8.2 
ROI8 89.98 8.2 
ROI9 217.94 15.23 
ROI10 224.12 15.23 
ROI11 210.85 15.23 
ROI12 183.63 15.23 
ROI13 163.14 6.95 
ROI14 90.62 6.95 
ROI15 200.98 6.95 
ROI16 239.74 6.95 
ROI17 215.61 7.81 
ROI18 242.93 7.81 
ROI19 200.44 7.81 
ROI20 172.39 7.81 
ROI21 230.82 7.81 
ROI22 100.76 7.98 
ROI23 209.17 7.98 
ROI24 196.58 7.98 
ROI25 80.64 7.98 
ROI26 200.32 9.42 
ROI27 216.18 9.42 
ROI28 183.82 9.42 
ROI29 176.99 9.42 
ROI30 234.65 8.66 
ROI31 119.59 8.66 
ROI32 187.36 8.66 
ROI33 200.51 8.66 
ROI34 214.12 9.41 
ROI35 164.93 9.41 
ROI36 167.26 9.41 
ROI37 188.72 9.41 
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ROI38 194.58 9.41 
ROI39 218.61 9.41 
ROI40 105.49 7.29 
ROI41 185.38 7.29 
ROI42 153.73 7.29 
ROI43 249.03 7.29 
ROI44 194.28 8.04 
ROI45 243.84 8.04 
ROI46 128.42 10.82 
ROI47 220.37 10.82 
ROI48 196.75 10.82 
ROI49 230.49 8.3 
ROI50 159.9 8.3 
ROI51 213.12 8.3 
ROI52 184.93 8.3 
ROI53 191.19 9.71 
ROI54 167.33 9.71 
ROI55 242.73 9.71 
ROI56 214.61 11.55 
ROI57 188.41 11.55 
ROI58 199.49 11.55 
ROI59 200.36 11.55 
ROI60 167.42 9.09 
ROI61 100.94 9.09 
ROI62 163.2 9.09 
ROI63 199.05 9.09 
ROI64 164.06 9.09 
ROI65 190.37 8.24 
ROI66 203.84 8.24 
ROI67 172.43 8.24 
ROI68 222.93 8.24 
ROI69 172.04 9.56 
ROI70 118.33 9.56 
ROI71 170.26 12.95 
ROI72 186.95 12.95 
ROI73 200.21 10.28 
ROI74 214.35 8.46 
ROI75 204.82 8.46 
ROI76 226.04 8.46 
ROI77 173.95 9.43 
ROI78 177.52 9.43 
ROI79 188.67 8.27 
ROI80 250.81 8.27 
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